Positive Q1 trading update
Creo Medical Group plc reported a strong first quarter for fiscal year 2026, with revenue growing approximately 60% year-on-year, meeting management's expectations and reinforcing the outlook for 40% to 60% full-year revenue growth. The company also announced the sale and outsourcing of its manufacturing operations, which is projected to reduce underlying operating costs by 15% annually compared to fiscal year 2025. Commercial progress continues across the product portfolio, supported by clinical validation.
Select text to share a quote on X · sign in to keep highlights & notes in your CREO notes
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides a trading update for the three months ended 31 March 2026 (Q1 FY26).
Further to the update provided on 20 January 2026, the Company's growth momentum for the year ended 31 December 2025 (FY25) has continued, with a strong trading performance in Q1 FY26. Year-on-year revenue growth (Q1 FY26 vs Q1 FY25) was c.60%, the upper limit of management's expectations. This performance underpins management's view that the Company is on track to deliver 40% to 60% full year revenue growth during FY 2026.
Along with top line growth, management continues to focus on improving the operational efficiency of the business. Following the announcement of the sale and outsourcing of its manufacturing operations announced on 16 April 2026, the Company is expected to reduce underlying operating costs by 15% compared to FY25 on an annualised basis. Commercial progress continues to be made across the Company's product portfolio, supported by excellent clinical validation.
Creo's full year results for 2025 are expected to be announced in May 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.